Desernyl

Desernyl - General Information

An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Desernyl is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome. [PubChem]

Pharmacology of Desernyl

Desernyl has been shown, in vitro and in vivo, to inhibit or block the effects of serotonin, a substance which may be involved in the mechanism of vascular headaches. Serotonin has been variously described as a central neurohumoral agent or chemical mediator, as a "headache substance" acting directly or indirectly to lower pain threshold, as an intrinsic "motor hormone" of the gastrointestinal tract, and as a "hormone" involved in connective tissue reparative processes.

Desernyl for patients

Desernyl Interactions

Methysergide may reverse the analgesic activity of narcotic analgesics. Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.

Desernyl Contraindications

Hypersensitivity to the drug or to tartrazine (FD&C Yellow #5) or any other components of the formulation, pregnancy, lactation, peripheral vascular disease, severe arteriosclerosis, severe hypertension, coronary artery disease, phlebitis or cellulitis of the lower limbs, pulmonary disease, collagen diseases or fibrotic processes, impaired liver or renal function, valvular heart disease, debilitated states and serious infections.

Additional information about Desernyl

Desernyl Indication: For the treatment of vascular headache
Mechanism Of Action: Desernyl is serotonin antagonists acts on central nervous system (CNS), which directly stimulates the smooth muscle leading to vasoconstriction. Some alpha-adrenergic blocking activity has been reported. Suggestions have been made by investigators as to the mechanism whereby Desernyl produces its clinical effects, but this has not been finally established, although it may be related to the antiserotonin effect.
Drug Interactions: Acebutolol Ischemia with risk of gangrene
Atenolol Ischemia with risk of gangrene
Betaxolol Ischemia with risk of gangrene
Bevantolol Ischemia with risk of gangrene
Bisoprolol Ischemia with risk of gangrene
Carteolol Ischemia with risk of gangrene
Carvedilol Ischemia with risk of gangrene
Esmolol Ischemia with risk of gangrene
Labetalol Ischemia with risk of gangrene
Metoprolol Ischemia with risk of gangrene
Nadolol Ischemia with risk of gangrene
Oxprenolol Ischemia with risk of gangrene
Penbutolol Ischemia with risk of gangrene
Pindolol Ischemia with risk of gangrene
Propranolol Ischemia with risk of gangrene
Practolol Ischemia with risk of gangrene
Sotalol Ischemia with risk of gangrene
Timolol Ischemia with risk of gangrene
Zolmitriptan Possible severe and prolonged vasoconstriction
Sumatriptan Possible severe and prolonged vasoconstriction
Rizatriptan Possible severe and prolonged vasoconstriction
Naratriptan Possible severe and prolonged vasoconstriction
Almotriptan Possible severe and prolonged vasoconstriction
Eletriptan Possible severe and prolonged vasoconstriction
Frovatriptan Possible severe and prolonged vasoconstriction
Amyl Nitrite Possible antagonism of action
Erythrityl Tetranitrate Possible antagonism of action
Isosorbide Dinitrate Possible antagonism of action
Isosorbide Mononitrate Possible antagonism of action
Nitroglycerin Possible antagonism of action
Clarithromycin Risk of ergotism and severe ischemia with this association
Telithromycin Risk of ergotism and severe ischemia with this association
Troleandomycin Possible ergotism and severe ischemia with this combination
Erythromycin Possible ergotism and severe ischemia with this combination
Josamycin Possible ergotism and severe ischemia with this combination
Posaconazole Contraindicated co-administration
Sibutramine Possible serotoninergic syndrome
Efavirenz The antiretroviral agent may increase the ergot derivative toxicity
Delavirdine The antiretroviral agent may increase the ergot derivative toxicity
Food Interactions: Not Available
Generic Name: Methysergide
Synonyms: Methyllysergic acid butanolamide; Methysergid; Methysergidum [INN-Latin]; Metisergide [DCIT]; Metisergido [INN-Spanish]; N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide; N-(alpha-(Hydroxymethyl)propyl)-1-methyl-dextro-lysergamide
Drug Category: Vasoconstrictor Agents; Serotonin Antagonists; Sympatholytics
Drug Type: Small Molecule; Approved

Other Brand Names containing Methysergide: Deseril; Desernil; Desernyl; Deseryl; Sansert;
Absorption: Rapid
Toxicity (Overdose): Few cases of acute methysergide intoxication have been reported. The possible symptom complex is therefore not fully known. The following symptoms are based on these few case reports. Euphoria, hyperactivity, tachycardia, dilated pupils, and dizziness have been reported in a child with a dose of 20-24 mg of methysergide. In adults, peripheral vasospasm, with diminished or absent pulses, coldness, mottling and cyanosis, has been observed at a dose of 200 mg. Ischemic tissue damage has not been reported in acute overdosage with methysergide.
Protein Binding: Not Available
Biotransformation: Hepatic
Half Life: Not Available
Dosage Forms of Desernyl: Tablet Oral
Chemical IUPAC Name: Not Available
Chemical Formula: C21H27N3O2
Methysergide on Wikipedia: https://en.wikipedia.org/wiki/Methysergide
Organisms Affected: Humans and other mammals